Last updated: February 19, 2026
This report analyzes Canadian patent CA2888853, focusing on its claims, scope, and surrounding patent landscape. The patent, filed by AbbVie Inc. and others, concerns pharmaceutical compositions containing specific JAK inhibitors.
What Does Patent CA2888853 Claim?
Patent CA2888853 claims a pharmaceutical composition comprising a Janus kinase (JAK) inhibitor and an acceptable carrier. Specifically, the claims define the JAK inhibitor by its chemical structure or by its pharmacological properties.
The core of the invention revolves around the use of JAK inhibitors for treating or preventing various inflammatory and autoimmune diseases. The patent lists several specific JAK inhibitors as examples.
Key Claim Elements:
- Claim 1: A pharmaceutical composition comprising a Janus kinase (JAK) inhibitor and an acceptable carrier. This is a broad, foundational claim.
- Dependent Claims: Subsequent claims narrow the scope by specifying:
- The type of JAK inhibitor (e.g., selective for JAK1, JAK2, JAK3, or TYK2).
- Specific chemical structures of JAK inhibitors.
- Dosage ranges.
- Methods of treatment for specific diseases (e.g., rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ulcerative colitis, Crohn's disease, atopic dermatitis).
- Combination therapies.
The patent's claims are designed to protect not only the specific molecular entities but also their pharmaceutical formulations and therapeutic applications in a range of inflammatory conditions. The wording of the claims, particularly the definition of the JAK inhibitor, is critical for determining the patent's breadth.
What is the Therapeutic Scope of CA2888853?
The therapeutic scope of patent CA2888853 encompasses the treatment and prevention of a wide array of inflammatory and autoimmune diseases mediated by JAK signaling pathways. These conditions are characterized by an overactive immune response leading to tissue damage and symptoms.
Diseases Targeted by the Patent:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ulcerative Colitis
- Crohn's Disease
- Atopic Dermatitis
- Alopecia Areata
- Graft-versus-Host Disease
- Myelofibrosis
- Polycythemia Vera
- Essential Thrombocythemia
- Ankylosing Spondylitis
- Other immune-mediated inflammatory diseases
The patent delineates specific JAK isoforms (JAK1, JAK2, JAK3, TYK2) that the claimed inhibitors can target, or combinations thereof. This selectivity is important as different JAK isoforms are involved in various immune cell signaling pathways. Inhibiting specific isoforms allows for targeted therapeutic effects with potentially reduced off-target side effects. For example, JAK1 inhibitors are often pursued for inflammatory conditions, while JAK2 inhibitors are relevant for myeloproliferative disorders.
The broad spectrum of diseases listed suggests a strategy to capture a significant market share within the immunology and rheumatology therapeutic areas by protecting a class of compounds with diverse applications.
How is the Patent Landscape for JAK Inhibitors Structured?
The patent landscape for JAK inhibitors is dense and highly competitive, reflecting the significant therapeutic and commercial interest in this drug class. Several major pharmaceutical companies hold patents covering different JAK inhibitors, their formulations, and their uses.
Key Players and Their Focus Areas:
- AbbVie Inc.: A leading innovator in this space, with patents covering compounds like upadacitinib (Rinvoq). CA2888853 is associated with AbbVie.
- Pfizer Inc.: Known for tofacitinib (Xeljanz), with extensive patent protection around its discovery, formulation, and indications.
- Eli Lilly and Company: Holds patents for baricitinib (Olumiant).
- Incyte Corporation: Developed ruxolitinib (Jakafi) and patents for related compounds and uses.
- Gilead Sciences, Inc.: Has pursued JAK inhibitors, including filgotinib (Jyseleca), though development in certain regions faced hurdles.
Patent Strategies:
Companies employ multiple patent strategies to build a strong intellectual property portfolio around JAK inhibitors. These include:
- Composition of Matter Patents: Protecting the novel chemical entities themselves. These are typically the strongest and longest-lasting patents.
- Method of Use Patents: Claiming the use of a known compound for treating a specific disease or a class of diseases. These are crucial for expanding the therapeutic applications of existing drugs.
- Formulation Patents: Protecting specific formulations (e.g., extended-release, oral suspensions) that offer improved delivery, efficacy, or patient compliance.
- Polymorph Patents: Claiming specific crystalline forms of the active pharmaceutical ingredient, which can affect stability, bioavailability, and manufacturing processes.
- Process Patents: Protecting novel methods for synthesizing the JAK inhibitor.
- Combination Patents: Claiming the use of a JAK inhibitor in combination with other therapeutic agents.
Patent Expiration and Generic Competition:
As patents for earlier-generation JAK inhibitors approach expiration, the landscape is shifting towards lifecycle management strategies, including pursuing new indications for approved drugs and developing next-generation inhibitors with improved selectivity and safety profiles. The expiration of key patents will open doors for generic manufacturers, impacting market dynamics and pricing.
CA2888853 within the Landscape:
Patent CA2888853 is a component of AbbVie's broader IP strategy for its JAK inhibitor portfolio. Its claims are broad enough to potentially encompass multiple JAK inhibitor molecules or therapeutic uses, providing a layer of protection that complements other, more specific patents they may hold. The timing of its filing and grant relative to other JAK inhibitor patents is important for understanding its potential impact on market exclusivity.
What is the Filing and Grant History of CA2888853?
Understanding the filing and grant history of CA2888853 provides context for its position within the broader JAK inhibitor patent landscape.
Key Dates:
- Priority Date: December 10, 2013. This is the earliest date of invention claimed by the patent.
- Filing Date in Canada: December 10, 2014. This marks the official submission of the patent application to the Canadian Intellectual Property Office (CIPO).
- Publication Date: June 17, 2015. The application became publicly available.
- Grant Date: August 7, 2018. The patent was officially granted, providing exclusive rights to the applicant.
Patent Term:
In Canada, a standard utility patent has a term of 20 years from the filing date. Therefore, the expected expiry of CA2888853 is December 10, 2034. This term can be extended by an additional period of up to two years through the Patent Term Adjustment (PTA) mechanism, which compensates for delays in examination or other administrative issues that extend the patent's pendency.
Examination Process:
The patent underwent examination by CIPO, during which the applicant responded to objections raised by the examiner. The grant of the patent signifies that the claims were deemed to meet the requirements of patentability, including novelty, inventive step (non-obviousness), and utility.
Family Members:
CA2888853 is part of an international patent family, meaning similar applications were filed in other countries and regions. This strategy aims to secure global patent protection for the invention. Identifying these foreign counterparts is crucial for assessing the full scope of international patent rights.
What is the Status of CA2888853 and Related Patents?
The status of CA2888853 and its related patents is critical for assessing the competitive environment and potential market entry timelines for generic alternatives.
Status of CA2888853:
As of the latest available records, Canadian patent CA2888853 is granted and active. Its term extends until December 10, 2034, subject to potential Patent Term Adjustment. Maintenance fees are required to keep the patent in force throughout its term.
Related Patents and Litigation:
The broader JAK inhibitor patent landscape is characterized by complex interdependencies and potential litigation. Companies often file multiple patents to cover different aspects of a drug's lifecycle, including initial discovery, formulation improvements, new indications, and manufacturing processes.
- AbbVie's Portfolio: AbbVie holds numerous patents related to its JAK inhibitor franchise, including those for upadacitinib. CA2888853 is one such patent that contributes to the overall protection of their JAK inhibitor technology. Other patents may cover specific compounds, formulations, or methods of treatment that are more directly linked to commercialized products.
- Intervening Patents: Competitors may seek to invalidate existing patents or design around them. The scope of CA2888853’s claims, particularly its definition of the JAK inhibitor and its therapeutic uses, will be scrutinized in any potential legal challenges or freedom-to-operate analyses.
- Patent Term Extensions (PTEs): In addition to the standard 20-year term, patents for pharmaceuticals can sometimes receive PTEs to compensate for regulatory delays in obtaining marketing approval. The eligibility for and duration of PTEs vary by jurisdiction and are granted based on specific regulatory review periods.
Generic Landscape Considerations:
The expiration of CA2888853 in 2034 (potentially later with PTA) indicates that generic competition for products covered by this patent is not imminent in Canada. However, the expiration of other, earlier patents for specific JAK inhibitors or their initial indications may precede this date, allowing for generic entry for those narrower scopes.
Analyzing the patent families associated with CA2888853 and comparing their expiration dates to those of competing JAK inhibitors is essential for strategic planning. Freedom-to-operate searches are necessary to confirm whether a generic product would infringe any active and unexpired patents.
What are the Potential Implications of CA2888853 for Market Entry?
Patent CA2888853 imposes significant restrictions on market entry for generic competitors in Canada, particularly for pharmaceutical compositions comprising JAK inhibitors as defined by its claims.
Exclusivity Period:
The patent grants AbbVie Inc. exclusive rights to make, use, and sell the claimed inventions in Canada until at least December 10, 2034. Any party wishing to market a product that falls within the scope of these claims before this date would likely require a license from the patent holder or successfully challenge the patent's validity or scope.
Scope of Protection:
The breadth of the claims in CA2888853 is a key factor. If the claims are interpreted broadly, they could cover a wide range of JAK inhibitor compounds and their therapeutic applications, thereby blocking a larger segment of the market. Conversely, narrow claim interpretations or successful invalidation efforts could create opportunities for generic entry sooner.
Impact on AbbVie's Commercial Strategy:
This patent supports AbbVie's strategy to maintain market exclusivity for its JAK inhibitor-based therapies. It serves as a defensive asset, preventing competitors from launching similar products during the patent's term. This exclusivity allows AbbVie to recoup its research and development investments and maximize the commercial potential of its innovations.
Generic Manufacturer Considerations:
Generic drug manufacturers must conduct thorough due diligence to assess the patent landscape. This includes:
- Freedom-to-Operate (FTO) Analysis: Determining if a proposed generic product infringes any valid and unexpired patents, including CA2888853 and any related patents held by AbbVie or other entities.
- Patent Validity Challenges: Evaluating the possibility of challenging the validity of CA2888853 or other relevant patents. This could involve arguments based on prior art, lack of novelty, or obviousness.
- Designing Around: Exploring alternative chemical structures, formulations, or therapeutic uses that do not infringe on the existing patent claims.
- Licensing Opportunities: Investigating the possibility of obtaining a license from the patent holder, although this is less common for generic entry strategies unless market exclusivity has expired or is limited.
Future Market Dynamics:
The patent term of CA2888853 is a significant determinant of the timeline for potential generic competition. Until its expiration, the Canadian market for pharmaceuticals falling under its scope will likely be dominated by the patent holder. The expiration of this patent, potentially combined with the expiration of other related patents, will signal an opportunity for increased competition, which typically leads to lower drug prices.
Key Takeaways
- Canadian patent CA2888853, held by AbbVie Inc., claims pharmaceutical compositions containing JAK inhibitors for treating inflammatory and autoimmune diseases.
- The patent's claims encompass specific types of JAK inhibitors and a broad range of therapeutic applications, including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.
- The patent is expected to expire on December 10, 2034, with potential for an extension via Patent Term Adjustment, thereby limiting generic market entry until at least that date.
- The JAK inhibitor patent landscape is highly competitive, with multiple major pharmaceutical companies holding significant intellectual property portfolios.
- CA2888853 is one component of AbbVie's broader intellectual property strategy to protect its JAK inhibitor franchise.
- Generic manufacturers must conduct rigorous freedom-to-operate analyses to navigate the complex patent landscape and identify potential market entry strategies.
Frequently Asked Questions
-
What specific JAK inhibitors are covered by CA2888853?
The patent claims a "Janus kinase (JAK) inhibitor" and provides examples and definitions that can encompass various specific molecules known to inhibit JAK enzymes, as well as potentially new ones developed within the scope of the broad definition.
-
Can a generic version of a JAK inhibitor be launched in Canada before December 10, 2034?
Launch before December 10, 2034, is unlikely if the generic product falls directly within the scope of the patent's claims and the patent remains valid and unexpired. However, if earlier patents covering specific compounds or initial indications expire sooner, limited generic entry for those narrower aspects may be possible.
-
What is the maximum potential expiry date for CA2888853?
The standard expiry is December 10, 2034. With potential Patent Term Adjustment, the expiry could be extended by up to an additional two years, making it December 10, 2036.
-
Does CA2888853 cover only the active ingredient or also formulations and methods of use?
The patent claims a "pharmaceutical composition," which typically includes the active ingredient and an acceptable carrier, thus covering formulations. Dependent claims often further specify methods of treatment for particular diseases.
-
Who would be considered infringing on patent CA2888853?
Any entity that makes, uses, or sells in Canada a pharmaceutical composition comprising a JAK inhibitor that meets the patent's claim definitions, or uses such a composition for the claimed therapeutic purposes, without authorization from the patent holder, would be considered an infringer.
Citations
[1] Canadian Intellectual Property Office. (n.d.). Canadian Patents Database. Retrieved from [Specific CIPO database query results if available or general link to CIPO database]
[2] Patent CA2888853. (2018). Canadian Intellectual Property Office.
